• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Table 9.12Repaglinide vs nateglinide

1 study83 N=150

Level of evidence 1+

HbA1cFinal HbA1c levels were 0.99% lower in the repaglinide group than in the placebo group (p<0.001)
FPGThere was a mean 1.44 mmol/l greater reduction in the repaglinide group compared with the placebo group (p<0.001)
Post load glucose/PPBGNE
Lipid profileTCLDLTGHDL
NENENENE
BMI/body weightBMIBody weight
NENS
AEsThe overall tolerability of repaglinide was similar to placebo excluding hypoglycaemic events
Hypoglycaemia
17% of patients in the repaglinide group and 3% in the placebo group reported minor episodes of hypoglycaemia
3 repaglinide patients reported a total of 4 major hypoglycaemic events

From: 9, Oral glucose control therapies (1): metformin, insulin secretagogues, and acarbose

Cover of Type 2 Diabetes
Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (Update).
NICE Clinical Guidelines, No. 66.
National Collaborating Centre for Chronic Conditions (UK).
Copyright © 2008, Royal College of Physicians of London.

All rights reserved. No part of this publication may be reproduced in any form (including photocopying or storing it in any medium by electronic means and whether or not transiently or incidentally to some other use of this publication) without the written permission of the copyright owner. Applications for the copyright owner’s written permission to reproduce any part of this publication should be addressed to the publisher.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.